Follow Centene to never miss an important update.
Centene's Illinois health plan, Meridian, is launching a multiyear partnership with the nonprofit March of Dimes. The funding will support a new mobile medical unit and community events designed to provide resources and care for expectant mothers. While this is a positive community initiative, the 1.2 million dollar cost is very small for a company that brings in billions of dollars in revenue. For long-term owners, this is a routine part of how managed care companies maintain the local relationships and health outcomes required to keep their government contracts.
Source: PRNewsWire
The US Department of Justice has stepped into a whistleblower lawsuit against Centene. These cases are brought by private individuals on behalf of the government, and the Department of Justice only intervenes when it believes the case has enough merit or importance to warrant federal resources.
While the specific allegations were not detailed in the initial announcement, government intervention usually increases the risk of a settlement or fine. For a company like Centene that relies heavily on government-funded programs like Medicaid and Medicare, maintaining a clean relationship with federal regulators is vital for winning future contracts.
Source: Business Wire
A Democratic sweep of Congress has shifted the outlook for government-funded health programs. This is particularly relevant for Centene because it earns the vast majority of its revenue from Medicaid and the Affordable Care Act (ACA) Marketplace. These programs often face funding threats or structural changes when Republican administrations have full legislative control.
While market futures rose on the news, the real impact for this company is a likely period of stability for its core business. With a Democratic Congress, the risk of aggressive cuts to Medicaid eligibility or the removal of ACA subsidies is much lower. This provides a clearer path for management to focus on its plan to improve profit margins without fighting major policy changes at the same time.
Source: Bloomberg Markets and Finance
After Centene reported its October results, we updated our fair value and cut our quality score to 2.4. We moved our rating to Watch and lowered our projections for how many customers the company serves after commercial membership fell 38% in the past year. We have added the cost of staff cuts and vendor fees to what we track, and we now account for the growth in Medicare prescription drug plans. We also raised our expectation for the share of premiums the company spends on medical claims over the next year.
Centene reported adjusted earnings of $0.58 per share, well ahead of the $0.10 analysts expected. Revenue reached $50.65 billion, also topping forecasts. The company raised its full-year profit outlook to at least $5.20 per share, up from its previous target. The stock rose about 3 percent following the report.
A key metric for health insurers is the medical loss ratio, which measures the percentage of premiums paid out for healthcare claims. Centene reported a ratio of 92.7 percent for the quarter. While that sounds high, it was better than the company expected, particularly in its Medicare business. This suggests that the recent surge in medical costs that has pressured the entire industry may be starting to level off. The company also used its cash to pay down $1.1 billion in debt since June. For long-term owners, this combination of better-than-expected cost control and a stronger balance sheet supports the view that Centene is successfully managing through a period of shifting government contracts and rising healthcare use.
See the full quarter, and how our tracked metrics did
Source: 8-K filing
Management has a long record of setting a low bar and clearing it, often beating their own profit targets by wide margins even as they navigate complex changes to government health programs.
| Expectation | |
|---|---|
| EPS | $-1.16 |
| Revenue | $46.30B |